ChemoMetec A/S (CPH:CHEMM)
Denmark · Delayed Price · Currency is DKK | Market Cap | 8.86B -20.3% |
| Revenue (ttm) | 511.06M +3.1% |
| Net Income | 201.84M +15.5% |
| EPS | 11.60 +15.6% |
| Shares Out | 17.20M |
| PE Ratio | 44.40 |
| Forward PE | 41.20 |
| Dividend | 7.00 (1.36%) |
| Ex-Dividend Date | Oct 10, 2025 |
| Volume | 34,889 |
| Open | 525.50 |
| Previous Close | 525.00 |
| Day's Range | 511.50 - 529.00 |
| 52-Week Range | 235.20 - 804.00 |
| Beta | 1.39 |
| Analysts | Strong Buy |
| Price Target | 635.00 (+23.3%) |
| Earnings Date | Sep 10, 2026 |
About ChemoMetec
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202... [Read more]
Financial Performance
In fiscal year 2026, ChemoMetec's revenue was 511.06 million, an increase of 3.12% compared to the previous year's 495.57 million. Earnings were 201.84 million, an increase of 15.53%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CHEMM stock is "Strong Buy." The 12-month stock price target is kr 635.00, which is an increase of 23.30% from the latest price.
News
ChemoMetec Transcript: Q4 25/26
Revenue grew 3% to DKK 511 million, led by strong instrument sales, especially XcytoMatic and NC-203, while EBITDA margin rose to 55%. Guidance for FY 2026/2027 anticipates 7–13% revenue growth, driven by instrument replacements and automation, with continued investment in software and partnerships.
ChemoMetec Annual report: Q4 2026
ChemoMetec has published its Q4 2026 annual report on September 11, 2026.
Chemometec downgraded to Hold from Buy at SEB Equities
SEB Equities downgraded Chemometec (CHHMF) to Hold from Buy with a DKK 500 price target
ChemoMetec Appoints Price As CFO, Nikolajsen To Resign
(RTTNews) - ChemoMetec A/S, a biotechnology company, on Saturday announced the appointment on Phillip Massie Price as the new Chief Financial Officer (CFO), effective from August 3, 2026.
ChemoMetec Quarterly report: Q3 2026
ChemoMetec has published its Q3 2026 quarterly earnings report on May 6, 2026.
Chemometec upgraded to Buy from Hold at SEB Equities
SEB Equities upgraded Chemometec (CHHMF) to Buy from Hold with a DKK 400 price target
Chemometec price target lowered to DKK 900 from DKK 970 at Berenberg
Berenberg lowered the firm’s price target on Chemometec (CHHMF) to DKK 900 from DKK 970 and keeps a Buy rating on the shares.
ChemoMetec Quarterly report: Q2 2026
ChemoMetec has published its Q2 2026 quarterly earnings report on February 4, 2026.
ChemoMetec Transcript: Q1 25/26
Revenue grew 8% year-over-year with strong XM platform adoption and improved margins. Upgraded guidance reflects broad customer interest, with larger XM orders expected by fiscal year-end. Strategic focus is on software and automation, supporting long-term profitability.
ChemoMetec Earnings release: Q1 2026
ChemoMetec released its Q1 2026 earnings on November 7, 2025, summarizing the period's financial results.